問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

更新時間：2023-09-19

莊博雅
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

39Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

莊博雅

List

48Cases

2023-07-01 - 2029-07-01

Phase III

Active
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator's Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1)

  • Condition/Disease

    Follicular Lymphoma (FL)

  • Test Drug

    Odronextamab

Participate Sites
12Sites

Recruiting12Sites

2023-08-01 - 2029-06-30

Phase III

Active
A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Versus Standard of Care Therapy in Participants With Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4)

  • Condition/Disease

    B-Cell Non-Hodgkin Lymphoma (B-NHL)

  • Test Drug

    Odronextamab (REGN1979)

Participate Sites
11Sites

Not yet recruiting8Sites

Recruiting2Sites

2023-06-01 - 2028-11-27

Phase III

Active
A Phase 3, Open label, Randomized Study Comparing the Efficacy and Safety of Odronex tamab (REGN1979), an anti-CD20 × anti- CD3 bispecific antibody, in Combination with CHOP (Odro-CHOP) versus Rituximab in combination with CHOP (R-CHOP) in Previously Untreated Participants with Diffuse Large Bcell Lymphoma (DLBCL) (OLYMPIA-3)

  • Condition/Disease

    Previously Untreated Participants with Diffuse Large Bcell Lymphoma (DLBCL)

  • Test Drug

    injection

Participate Sites
9Sites

Recruiting9Sites

2019-04-01 - 2027-11-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-09-01 - 2027-06-30

Phase I

Active
A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-992 in Subjects with Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    solution

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

2025-08-01 - 2029-02-08

Phase I

Active
A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-902 in Participants with Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    injective

Participate Sites
3Sites

Recruiting3Sites

2025-06-01 - 2028-05-31

Phase III

Not yet recruiting
A Phase 3, Randomized, Multicenter, Parallel-arm, Double-blind Study to Compare Efficacy and Safety of EG1206A (EirGenix’ Pertuzumab) and Perjeta® (Pertuzumab) Sourced from EU as Neoadjuvant Treatment in Combination with Trastuzumab and Chemotherapy in Patients with HER2-positive Hormone Receptor-negative Early Breast Cancer

  • Condition/Disease

    HER2-positive Hormone Receptor-negative Early Breast Cancer

  • Test Drug

    injection

Participate Sites
11Sites

Recruiting11Sites

2024-10-25 - 2026-12-31

Phase I

Active
A Phase 1b Study to Evaluate HMBD-001 in Combination with Docetaxel with or without Cetuximab in Participants with Advanced Squamous Non-Small Cell Lung Cancers, and HMBD-001 in Combination with Cetuximab in Participants with Advanced Squamous Cell Cancers

  • Condition/Disease

    Cetuximab in Participants with Advanced Squamous Cell Cancers

  • Test Drug

    injective

Participate Sites
4Sites

Recruiting4Sites

2022-01-01 - 2024-08-08

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting1Sites

Terminated2Sites

2023-06-30 - 2029-02-28

Phase III

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy

  • Condition/Disease

    Locally Advanced or Unresectable Metastatic Breast Cancer 、Stage IV Breast Cancer

  • Test Drug

    Trodelvy

Participate Sites
10Sites

Not yet recruiting10Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB